Takeda Pharmaceutical
299 hedge funds and large institutions have $954M invested in Takeda Pharmaceutical in 2024 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 101 increasing their positions, 94 reducing their positions, and 42 closing their positions.
4,520% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $496K
19% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 42
7% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 94
0% more funds holding
Funds holding: 298 → 299 (+1)
0.26% less ownership
Funds ownership: 4.79% → 4.53% (-0.26%)
6% less capital invested
Capital invested by funds: $1.02B → $954M (-$62.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$21.8M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$9.34M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$7.01M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$6.83M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
-$70M |
| 2 |
Millennium Management
New York
|
-$19.3M |
| 3 |
CCM
Causeway Capital Management
Los Angeles,
California
|
-$10.4M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7.33M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$6.33M |
TAK Hedge Fund Activity: Q4 2024 in Review
299 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2024, worth a combined $954M — down 6.1% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new TAK positions and 42 closed out — a net gain of 8 holders — while 101 added to existing stakes and 94 trimmed.
The largest buyer was UBS Group, adding an estimated $21.8M. The largest seller was Mondrian Investment Partners, cutting an estimated $70M.
- 299 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2024, up from 298 in Q3 2024.
- Funds reported $954M of Takeda Pharmaceutical stock for Q4 2024, down 6.1% quarter-over-quarter.
- 50 funds opened new Takeda Pharmaceutical positions in Q4 2024 and 42 closed out, a net change of +8 holders.
- The largest Takeda Pharmaceutical buyer in Q4 2024 was UBS Group, an estimated $21.8M added.
- The largest Takeda Pharmaceutical seller in Q4 2024 was Mondrian Investment Partners, an estimated $70M sold.
Based on aggregated 13F filings for Q4 2024.